[1] |
SMYK DS, RIGOPOULOU EI, LLEO A, et al. Immunopathogenesis of primary biliary cirrhosis: an old wives’ tale[J]. Immun Ageing, 2011, 8( 1): 12. DOI: 10.1186/1742-4933-8-12.
|
[2] |
KIM WR, LINDOR KD, LOCKE GR 3rd, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community[J]. Gastroenterology, 2000, 119( 6): 1631- 1636. DOI: 10.1053/gast.2000.20197.
|
[3] |
WATSON RG, ANGUS PW, DEWAR M, et al. Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group[J]. Gut, 1995, 36( 6): 927- 930. DOI: 10.1136/gut.36.6.927.
|
[4] |
TANAKA A, MA X, YOKOSUKA O, et al. Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016[J]. Hepatol Int, 2016, 10( 6): 909- 915. DOI: 10.1007/s12072-016-9767-9.
|
[5] |
LLEO A, JEPSEN P, MORENGHI E, et al. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis[J]. Sci Rep, 2016, 6: 25906. DOI: 10.1038/srep25906.
|
[6] |
JOHN BV, AITCHESON G, SCHWARTZ KB, et al. Male sex is associated with higher rates of liver-related mortality in primary biliary cholangitis and cirrhosis[J]. Hepatology, 2021, 74( 2): 879- 891. DOI: 10.1002/hep.31776.
|
[7] |
FAN XL, WANG TT, SHEN Y, et al. Underestimated male prevalence of primary biliary cholangitis in China: Results of a 16-yr cohort study involving 769 patients[J]. Sci Rep, 2017, 7: 6560. DOI: 10.1038/s41598-017-06807-7.
|
[8] |
GERSHWIN ME, SELMI C, WORMAN HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients[J]. Hepatology, 2005, 42( 5): 1194- 202. DOI: 10.1002/hep.20907.
|
[9] |
LEUNG PS, WANG J, NAIYANETR P, et al. Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA[J]. J Autoimmun, 2013, 41: 79- 86. DOI: 10.1016/j.jaut.2012.12.007.
|
[10] |
TANAKA A, LEUNG PSC, GERSHWIN ME. Pathogen infections and primary biliary cholangitis[J]. Clin Exp Immunol, 2019, 195( 1): 25- 34. DOI: 10.1111/cei.13198.
|
[11] |
SHIMODA S, NAKAMURA M, ISHIBASHI H, et al. Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis[J]. Gastroenterology, 2003, 124( 7): 1915- 1925. DOI: 10.1016/s0016-5085(03)00387-1.
|
[12] |
FLOREANI A, NACCARATO R, CHIARAMONTE M. Prevalence of familial disease in primary biliary cirrhosis in Italy[J]. J Hepatol, 1997, 26( 3): 737- 738. DOI: 10.1016/s0168-8278(97)80444-8.
|
[13] |
JONES DE, WATT FE, METCALF JV, et al. Familial primary biliary cirrhosis reassessed: A geographically-based population study[J]. J Hepatol, 1999, 30( 3): 402- 407. DOI: 10.1016/s0168-8278(99)80097-x.
|
[14] |
TSUCHIYA N, OHASHI J. Human immune system diversity and its implications in diseases[J]. J Hum Genet, 2015, 60( 11): 655- 656. DOI: 10.1038/jhg.2015.101.
|
[15] |
NAKAMURA M, YASUNAMI M, KONDO H, et al. Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis(PBC): The HLA-DRB1polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC[J]. Hepatol Res, 2010, 40( 5): 494- 504. DOI: 10.1111/j.1872-034X.2010.00631.x.
|
[16] |
UMEMURA T, JOSHITA S, ICHIJO T, et al. Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis[J]. Hepatology, 2012, 55( 2): 506- 511. DOI: 10.1002/hep.24705.
|
[17] |
ZHAO DT, LIAO HY, ZHANG X, et al. Human leucocyte antigen alleles and haplotypes and their associations with antinuclear antibodies features in Chinese patients with primary biliary cirrhosis[J]. Liver Int, 2014, 34( 2): 220- 226. DOI: 10.1111/liv.12236.
|
[18] |
YASUNAMI M, NAKAMURA H, TOKUNAGA K, et al. Principal contribution of HLA-DQ alleles, DQB1*06:04 and DQB1*03:01, to disease resistance against primary biliary cholangitis in a Japanese population[J]. Sci Rep, 2017, 7( 1): 11093. DOI: 10.1038/s41598-017-11148-6.
|
[19] |
WANG C, ZHENG XD, TANG RQ, et al. Fine mapping of the MHC region identifies major independent variants associated with Han Chinese primary biliary cholangitis[J]. J Autoimmun, 2020, 107: 102372. DOI: 10.1016/j.jaut.2019.102372.
|
[20] |
CORDELL HJ, FRYETT JJ, UENO K, et al. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs[J]. J Hepatol, 2021, 75( 3): 572- 581. DOI: 10.1016/j.jhep.2021.04.055.
|
[21] |
ASSELTA R, PARABOSCHI EM, GERUSSI A, et al. X chromosome contribution to the genetic architecture of primary biliary cholangitis[J]. Gastroenterology, 2021, 160( 7): 2483- 2495. e 26. DOI: 10.1053/j.gastro.2021.02.061.
|
[22] |
HITOMI Y, NAKAMURA M. The genetics of primary biliary cholangitis: A GWAS and Post-GWAS update[J]. Genes(Basel), 2023, 14( 2): 405. DOI: 10.3390/genes14020405.
|
[23] |
OKADA Y, WU D, TRYNKA G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery[J]. Nature, 2014, 506( 7488): 376- 381. DOI: 10.1038/nature12873.
|
[24] |
ZHANG JZ, JIANG KW, LV L, et al. Use of genome-wide association studies for cancer research and drug repositioning[J]. PLoS One, 2015, 10( 3): e0116477. DOI: 10.1371/journal.pone.0116477.
|
[25] |
IMAMURA M, TAKAHASHI A, YAMAUCHI T, et al. Genome-wide association studies in the Japanese population identify seven novel loci for type 2 diabetes[J]. Nat Commun, 2016, 7: 10531. DOI: 10.1038/ncomms10531.
|
[26] |
POUPON RE, CHRÉTIEN Y, CHAZOUILLÈRES O, et al. Quality of life in patients with primary biliary cirrhosis[J]. Hepatology, 2004, 40( 2): 489- 494. DOI: 10.1002/hep.20276.
|
[27] |
FILLER K, LYON D, BENNETT J, et al. Association of mitochondrial dysfunction and fatigue: A review of the literature[J]. BBA Clin, 2014, 1: 12- 23. DOI: 10.1016/j.bbacli.2014.04.001.
|
[28] |
TALWALKAR JA, SOUTO E, JORGENSEN RA, et al. Natural history of pruritus in primary biliary cirrhosis[J]. Clin Gastroenterol Hepatol, 2003, 1( 4): 297- 302.
|
[29] |
PHILLIPS JR, ANGULO P, PETTERSON T, et al. Fat-soluble vitamin levels in patients with primary biliary cirrhosis[J]. Am J Gastroenterol, 2001, 96( 9): 2745- 2750. DOI: 10.1111/j.1572-0241.2001.04134.x.
|
[30] |
KAPLAN MM, GERSHWIN ME. Primary biliary cirrhosis[J]. N Engl J Med, 2005, 353( 12): 1261- 1273. DOI: 10.1056/NEJMra043898.
|
[31] |
BIZZARO N, COVINI G, ROSINA F, et al. Overcoming a“probable” diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: Study of 100 sera and review of the literature[J]. Clin Rev Allergy Immunol, 2012, 42( 3): 288- 297. DOI: 10.1007/s12016-010-8234-y.
|
[32] |
MATTALIA A, QUARANTA S, LEUNG PSC, et al. Characterization of antimitochondrial antibodies in healthy adults[J]. Hepatology, 1998, 27( 3): 656- 661. DOI: 10.1002/hep.510270303.
|
[33] |
SHIBATA M, ONOZUKA Y, MORIZANE T, et al. Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture[J]. J Gastroenterol, 2004, 39( 3): 255- 259. DOI: 10.1007/s00535-003-1285-6.
|
[34] |
DAHLQVIST G, GAOUAR F, CARRAT F, et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis[J]. Hepatology, 2017, 65( 1): 152- 163. DOI: 10.1002/hep.28859.
|
[35] |
YANG F, YANG Y, WANG Q, et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210[J]. Aliment Pharmacol Ther, 2017, 45( 5): 733- 743. DOI: 10.1111/apt.13927.
|
[36] |
European Association for the Study of the Liver. EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67( 1): 145- 172. DOI: 10.1016/j.jhep.2017.03.022.
|
[37] |
CHAZOUILLÈRES O, WENDUM D, SERFATY L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy[J]. Hepatology, 1998, 28( 2): 296- 301. DOI: 10.1002/hep.510280203.
|
[38] |
Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary biliary cholangitis(2021)[J]. J Clin Hepatol, 2022, 38( 1): 35- 41. DOI: 10.3969/j.issn.1001-5256.2022.01.007.
中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38( 1): 35- 41. DOI: 10.3969/j.issn.1001-5256.2022.01.007.
|